Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Hassan Website

Raffit Hassan, M.D.

Selected Publications

1)  Pastan I, Hassan R.
Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy.
Cancer Res. 74: 2907-2912, 2014.
[Journal]
2)  Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A, Kreitman RJ, Miettinen MM, Steinberg SM, Fowler DH, Pastan I.
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression.
Sci Transl Med. 5: 208ra147, 2013.
[Journal]
3)  Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D.
Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.
Clin. Cancer Res. 16: 6132-8, 2010.
[Journal]
4)  Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, Pastan I.
Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers.
Clin. Cancer Res. 13: 5144-9, 2007.
[Journal]
5)  Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, Pingpank J, Alexander R, Willingham M, Pastan I, Onda M.
Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer.
Clin. Cancer Res. 12: 447-53, 2006.
[Journal]
6)  Keenan BP, Saenger Y, Kafrouni MI, Leubner A, Lauer P, Maitra A, Rucki AA, Gunderson AJ, Coussens LM, Brockstedt DG, Dubensky TW, Hassan R, Armstrong TD, Jaffee EM.
A Listeria Vaccine and Depletion of T-regulatory Cells Activate Immunity Against Early-stage Pancreatic Intra-epithelial Neoplasms and Prolong Survival of Mice.
Gastroenterology. [Epub ahead of print], 2014.
[Journal]
7)  Reckamp KL, Giaccone G, Camidge DR, Gadgeel SM, Khuri FR, Engelman JA, Koczywas M, Rajan A, Campbell AK, Gernhardt D, Ruiz-Garcia A, Letrent S, Liang J, Taylor I, O'Connell JP, Jänne PA.
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
Cancer. 120: 1145-54, 2014.
[Journal]
8)  Thomas A, Lee JH, Abdullaev Z, Park KS, Pineda M, Saidkhodjaeva L, Miettinen M, Wang Y, Pack SD, Giaccone G.
Characterization of fibroblast growth factor receptor 1 in small-cell lung cancer.
J Thorac Oncol. 9: 567-71, 2014.
[Journal]
9)  Rajan A, Carter CA, Berman A, Cao L, Kelly RJ, Thomas A, Khozin S, Chavez AL, Bergagnini I, Scepura B, Szabo E, Lee MJ, Trepel JB, Browne SK, Rosen LB, Yu Y, Steinberg SM, Chen HX, Riely GJ, Giaccone G.
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.
Lancet Oncol. 15: 191-200, 2014.
[Journal]
10)  Jakopovic M, Thomas A, Lopez-Chavez A.
From platinum compounds to targeted therapies in advanced thoracic malignancies.
Anticancer Res. 34: 477-82, 2014.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 8/13/2014.